This study investigates the mechanisms that account for the adverse cardiovascular effects of the antitumor drug irinotecan. The activities of irinotecan, its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), and camptothecin were assayed in urethane-anesthetized rats to determine their effects on heart rate and blood pressure. In vitro experiments were performed to assess the effects of test drugs on acetylcholinesterase activity. Intravenous irinotecan (10 μmol/kg) decreased heart rate and blood pressure, but SN-38, camptothecin, or intracerebroventricular irinotecan had no effect. The bradycardic and hypotensive responses induced by irinotecan were abolished by bilateral vagotomy or atropine. Physostigmine caused a transient bradycardia, followed by a tachycardic response, and promoted a marked increment of blood pressure. Vagotomy or atropine prevented the bradycardic action of physostigmine, whereas the tachycardic and hypertensive responses were sensitive to atropine, but not to vagotomy. Five minutes after irinotecan administration (10 μmol/kg iv), its concentration in plasma and atrial tissue accounted for 2.29 ± 0.19 μmol/L and 1.08 ± 0.16 μmol/kg, respectively. The in vitro activity of human erythrocyte acetylcholinesterase was significantly inhibited by irinotecan (-21.5% at 100 μM) or physostigmine (-84.8% at 1 μM), whereas SN-38 or camptothecin had no effect. Rat atrial acetylcholinesterase was also significantly inhibited in vitro by irinotecan (-16.9% at 100 μM). The present results indicate that irinotecan exerts depressant effects on both heart rate and arterial blood pressure. A direct activation of cholinergic receptors or an interaction with central nervous sites does not appear to account for these inhibitory actions, whereas a blockade of acetylcholinesterase seems to occur at concentrations of irinotecan that may not be relevant in clinical settings. © 2001 Elsevier Science.

Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study / C. Blandizzi, B. DE PAOLIS, R. Colucci, A. DI PAOLO, R. Danesi, M. DEL TACCA. - In: TOXICOLOGY AND APPLIED PHARMACOLOGY. - ISSN 0041-008X. - 177:2(2001 Dec 01), pp. 149-156. [10.1006/taap.2001.9293]

Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study

R. Danesi;
2001

Abstract

This study investigates the mechanisms that account for the adverse cardiovascular effects of the antitumor drug irinotecan. The activities of irinotecan, its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), and camptothecin were assayed in urethane-anesthetized rats to determine their effects on heart rate and blood pressure. In vitro experiments were performed to assess the effects of test drugs on acetylcholinesterase activity. Intravenous irinotecan (10 μmol/kg) decreased heart rate and blood pressure, but SN-38, camptothecin, or intracerebroventricular irinotecan had no effect. The bradycardic and hypotensive responses induced by irinotecan were abolished by bilateral vagotomy or atropine. Physostigmine caused a transient bradycardia, followed by a tachycardic response, and promoted a marked increment of blood pressure. Vagotomy or atropine prevented the bradycardic action of physostigmine, whereas the tachycardic and hypertensive responses were sensitive to atropine, but not to vagotomy. Five minutes after irinotecan administration (10 μmol/kg iv), its concentration in plasma and atrial tissue accounted for 2.29 ± 0.19 μmol/L and 1.08 ± 0.16 μmol/kg, respectively. The in vitro activity of human erythrocyte acetylcholinesterase was significantly inhibited by irinotecan (-21.5% at 100 μM) or physostigmine (-84.8% at 1 μM), whereas SN-38 or camptothecin had no effect. Rat atrial acetylcholinesterase was also significantly inhibited in vitro by irinotecan (-16.9% at 100 μM). The present results indicate that irinotecan exerts depressant effects on both heart rate and arterial blood pressure. A direct activation of cholinergic receptors or an interaction with central nervous sites does not appear to account for these inhibitory actions, whereas a blockade of acetylcholinesterase seems to occur at concentrations of irinotecan that may not be relevant in clinical settings. © 2001 Elsevier Science.
Acetylcholinesterase; Blood pressure; Camptothecin; Heart rate; Irinotecan; Vagus nerve
Settore BIOS-11/A - Farmacologia
1-dic-2001
25-mag-2002
Article (author)
File in questo prodotto:
File Dimensione Formato  
05dffb84-402b-4813-9bdc-b02c0ef2250e.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 185.27 kB
Formato Adobe PDF
185.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1105549
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 7
  • OpenAlex ND
social impact